Sabine Wittemer-Rump

Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study

John Seibyl, Katharina Buerger, Osama Sabri, 2011, The Lancet Neurology.

Quantitative Systems Pharmacology Approaches for Immuno‐Oncology: Adding Virtual Patients to the Development Paradigm

Andy Z. X. Zhu, A. Rolfe, A. Kierzek, 2020, Clinical pharmacology and therapeutics.

In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients

A. Ochiai, T. Krahn, K. Ziegelbauer, 2017, Gastric Cancer.

First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody–Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer

Sung-Bae Kim, J. Berlin, F. Meric-Bernstam, 2019, Targeted Oncology.

Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors.

H. Huynh, A. Sommer, S. Hammer, 2016, Cancer research.

Phase 1 study of pasotuxizumab (BAY 2010112), a PSMA-targeting Bispecific T cell Engager (BiTE) immunotherapy for metastatic castration-resistant prostate cancer (mCRPC).

A. Buck, K. Miller, P. Kufer, 2019, Journal of Clinical Oncology.